PMID: 36905787

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.

ESMO open

Villaruz, L C LC, Wang, X X, Bertino, E M EM, Gu, L L, Antonia, S J SJ, Burns, T F TF, Clarke, J J, Crawford, J J, Evans, T L TL, Friedland, D M DM, Otterson, G A GA, Ready, N E NE, Wozniak, A J AJ, Stinchcombe, T E TE

2023-03-09

5 variants were identified in this publication

Variant ID	Gene	cDNA	Protein	Consequence	Exon	Intron
7-55241707-GGC-TGA	EGFR	c.2155_2157delGGCinsTGA	p.G719*	Nonsense	18/28	-
7-55259524-T-A	EGFR	c.2582T>A	p.L861Q	Missense	21/28	-
7-55241708-G-C	EGFR	c.2156G>C	p.G719A	Missense	18/28	-
7-55241677-G-T	EGFR	c.2125G>T	p.E709*	Nonsense	18/28	-
7-55249005-G-T	EGFR	c.2303G>T	p.S768I	Missense	20/28	-